12:00 AM
Jan 17, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

rhATIII: Phase III

In a 52-patient European Phase III trial, rhATIII treatment significantly reduced the use of fresh frozen plasma in heparin-resistant CPB patients, the trial's primary end point. A total of 6 of 28 patients in the rhATIII group...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >